Home > Result Summaries: Compounds > lamivudine Result Summaries: lamivudine GSKStudy ID Phase Title Summary (Download) 101822 Phase 3 See Detailed Description (0 citation(s)) 105816 Phase 4 A post-marketing surveillance to monitor the safety of 3TCTM (Lamivudine 150mg) administered in Korean subjects according to the prescribing information (0 citation(s)) 111945_1 N/A Studies using DAD - HIV and Hepatitis Coinfection Initiative (5 citation(s)) 111950_1 n\a Fractures over time stratified by HIV infection and Antiretroviral Therapy (ART) exposure (0 citation(s)) 112184 phase 4 An observational study to measure health-related quality of life (QoL) in chronic hepatitis B (0 citation(s)) 112295 N/A Drug Use Investigation for Epivir tablet (HRD Cooperative Investigation) (0 citation(s)) 112298 Phase 2 Special Drug Use Investigation for Epivir tablet (Pregnancy) (HRD Cooperative Investigation) (0 citation(s)) 112330 phase 2 Drug Use Investigation for Epzicom tablet (HRD Cooperative Investigation) (0 citation(s)) 112331 N/A Drug Use Investigation of Zefix Tablets (0 citation(s)) 112333 N/A Special Use Investigation of Zefix Tablets (0 citation(s)) 112335 phase 4 Special Drug Use Investigation for ZEFIX (lamivudine) tablet (HBV Cirrhosis) (1 citation(s)) 112348 phase 4 Special Drug Use Investigation for EPZICOM® (abacavir sulfate/lamivudine) tablet (Pregnancy) (HRD Cooperative Investigation) (0 citation(s)) 112872_1 n\a HIV treatment and CVD events - Ingenix. Retrospective Database Analysis of Patients with Human Immunodeficiency Virus (HIV) Treatment and Cardiovascular Disease (CVD) Events (0 citation(s)) 112874_1 N/A Incidence and Risk Factors for New-onset Diabetes in HIV-infected Patients. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study (1 citation(s)) 112877_3 N/A Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration (5 citation(s)) 112878_2 N/A Diabetes Mellitus, Preexisting Coronary Heart Disease, and the Risk of Subsequent Coronary Heart Disease Events in Patients Infected With Human Immunodeficiency Virus (2 citation(s)) 112884_1 N/A The metabolic syndrome in the DAD Study (2 citation(s)) 112885_1 N/A Antiretroviral Pregnancy Registry (APR)-Risk of birth defects associated with exposure to GSK HIV drugs during pregnancy (1 citation(s)) 112886_2 N/A Changes over time in risk factors for cardiovascular disease and use of Lipid-Lowering drugs in HIV-infected individuals and impact on myocardial infarction. (0 citation(s)) 112887_1 N/A Studies using DAD - Effects of different interventions to improve ART-associated dyslipidemia (1 citation(s)) 112889_2 N/A HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies (0 citation(s)) 113039_1 N/A Studies using DAD - Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles? (1 citation(s)) 113154_1 N/A Predictors of hypertension and changes of blood pressure in HIV-infected patients (2 citation(s)) 113156_1 N/A Studies using the VA - Studies done under the Oversight Committee for the Evaluation of the metabolic complications of HAART (2 citation(s)) 113329_1 n\a Lactic acid levels in children pre- and perinatally treated with antiretrovirals to prevent HIV transmission (Giaquinto; Hyperlactatemia in infants with in utero exposure to ZDV/3TC ) (2 citation(s)) 113973 n\a A retrospective cohort study to evaluate the rate of good responses to lamivudine (LAM) treatment in naïve Chronic Hepatitis B (CHB) patients with certain pre-treatment characteristics (0 citation(s)) 114957 phase 1 A Randomized, Open-label, Single-dose, Two-period, Crossover Study to Demonstrate the Bioequivalence of the Fixed Dose Combination (FDC) of lamivudine and adefovir dipivoxil (100mg/10mg) to Heptodin® (100mg ) and Hepsera® (10mg) (1 citation(s)) 115325 phase 1 A Randomized, Open-Label, Crossover Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™ Administered Concurrently in Healthy Adult Subjects (0 citation(s)) C93-015 Phase 1 A Study to Investigate the Pharmacokinetics of Lamivudine (GR109714X) in Patients with Impaired Hepatic Function (0 citation(s)) COLA4005 Phase 2 A Phase II, Open-Label, Randomized Study of the Efficacy and Safety of EPIVIR 150mg Twice-Daily Versus EPIVIR 300mg Once-Daily When Administered for 24 Weeks in Combination with FDA-Approved Dosage Regimens of ZERIT and Either CRIXIVAN or VIRACEPT in Subjects with HIV-1 Infection (1 citation(s)) EPV10001 Phase 1 An Open-Label, Randomized, 2-way Cross-over Study to Compare the Steady-State Pharmacokinetics of Lamivudine and Lamivudine Triphosphate Following Lamivudine 300mg Once Daily Versus EPIVIR 150mg Twice a Day in Healthy Volunteers (2 citation(s)) EPV20001 Phase 3 A Phase II/III 48-Week, Randomized, Double-Blind, Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Lamivudine 300mg QD vs Lamivudine 150mg BID in Combination with Zidovudine 300mg BID and Efavirenz 600mg QD in Antiretroviral-Naïve Adults with HIV-1 Infection. 48-Week Report (2 citation(s)) EPV40001 Phase 4 Open-Label, Pilot Study To Explore The Early Antiviral Activity And Tolerability Of Abacavir And Epivir When Each Is Administered Once-Daily Within A Triple Combination Regimen Including Abacavir, Epivir And Retrovir Compared to The Triple Combination Regimen Administered Twice-Daily In Antiretr ... (3 citation(s)) EPZ108859 phase 3 See Detailed Description (10 citation(s)) LAMPOL4002 Phase 4 A multicentre, open study to estimate the effect of Lamivudine on liver histology and HBV DNA clearance in patients with chronic hepatitis B (1 citation(s)) LB-01 Phase 2 Dose Finding Study on Lamivudine in Chronic Hepatitis B Patients (Protocol LB01) (0 citation(s)) LB-02 Phase 3 Phase III Study of Lamivudine - A Placebo-controlled, Double-blind Study of Lamivudine in Chronic Hepatitis B Patients - (Protocol No: LB-02) (1 citation(s)) LB-03 Phase 3 Phase III Study of Lamivudine - A Long-term Study of Lamivudine in Chronic Hepatitis B Patients - (Protocol No: LB-03) (1 citation(s)) LB-04 Phase 3 Phase III Clinical Trial of GG714 (Lamivudine): Histological Evaluation of Long-term Treatment - A Full Report of Extension Study - (Protocol No. LB-04) (1 citation(s)) LB-05 Phase 1 Comparison of Pharmacokinetic of Lamivudine Between Elderly Volunteers and Healthy Young Male Volunteers (Protocol LB-05) (0 citation(s)) LB-06 Phase 3 Phase III Study of Lamivudine - Follow-up Investigation after Double-blind Study (LB-02) and Long-term Study (LB-03) - (Protocol No.: LB-06) (1 citation(s)) M00026/012 Phase 2 An open, randomised, multicentre, phase II study to evaluate the safety and therapeutic efficacy of an investigational vaccination regimen versus Lamivudine in adult patients with HBeAg positive chronic Hepatitis B.Lamivudine (Lam): GlaxoSmithKline (GSK) Biologicals’ cytosine nucleoside analogue… (0 citation(s)) M00026/016 Phase 2 An open, randomised, multicentre, phase I/II study to evaluate the safety and therapeutic efficacy of an investigational vaccination regimen versus Lamivudine, in adult patients with HBeAg negative, anti-HBe antibody positive chronic… (0 citation(s)) M00026-012 Phase 2 An open, randomised, multicentre, phase II study to evaluate the safety and therapeutic efficacy of an investigational vaccination regimen versus Lamivudine in adult patients with HBeAg positive chronic Hepatitis B. (1 citation(s)) NUC 30956 Phase 4 AN OPEN STUDY OF LAMIVUDINE TREATMENT IN ADULT HBeAg NEGATIVE (presumed pre-core mutant) CHRONIC HEPATITIS B PATIENTS IN IRAN. (0 citation(s)) NUC105698 Phase 1 A post-marketing surveillance to monitor the safety of Zeffix(Lamivudine) administered in Korean chronic hepatitis B virus infection subjects according to the prescribing information (0 citation(s)) NUC10901 Phase 1 An Open Label Study of the Pharmacokinetics of Lamivudine (GR109714X) in Subjects Receiving Peritoneal Dialysis in Endstage Renal Failure (1 citation(s)) NUC10902 Phase 1 A randomized, open-label, cross-over study in Chinese healthy subjects, to establish bioequivalence between two formulations of Lamivudine (GR109714X) clinical trail material (0 citation(s)) NUC10905 Phase 1 A randomised, open label, cross-over study in Chinese healthy subjects, to establish bioequivalence between lamivudine oral solution and tablet (GR109714X) clinical trial material. (0 citation(s)) NUC20904 Phase 2 A randomised, stratified, double-blind, multicentre study of the safety and efficacy of 52 weeks treatment with adefovir dipivoxil and lamivudine for subjects with chronic hepatitis B who have developed hepatitis B virus variants and evidence of reduced therapeutic response to lamivudine (1 citation(s)) NUC20905 Phase 2 A Multicentre, Double-blind, Randomised, Placebo-controlled Pilot Study to Evaluate the Effect of Lamivudine on Serum HDV RNA in Subjects Co-infected with Hepatitis B and Delta Virus (1 citation(s)) NUC20912 Phase 2 A Phase II Study of Lamivudine Compared to Lamivudine Plus Adefovir Dipivoxil for Subjects With Chronic Hepatitis B (0 citation(s)) NUC20917 Phase 2 A double-blind, active-controlled, randomized 52-week extended follow-on study to investigate the long-term efficacy and safety of adefovir dipivoxil 10mg and lamivudine 100mg treatment for subjects with hepatitis B who have completed the previous Phase II protocol NUC20904 (1 citation(s)) NUC20921 Phase 2 Open-label compassionate access programme to provide adefovir dipivoxil and lamivudine to patients with Chronic Hepatitis B infection who are participating in or have completed, as appropriate, one of the following GlaxoSmithKline or Gilead Sciences Inc. clinical trials: NUC20917, NUC20912, NUCB4006, NUC40021 (0 citation(s)) NUC30902 Phase 3 A multicenter, prospective, descriptive study to compare the efficacy of lamivudine alone versus lamivudine plus anti-HB hyperimmune gammaglobulin in the prevention of hepatitis B virus reinfection after liver transplant. (7 citation(s)) NUC30903 Phase 3 A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of 52 Weeks Lamivudine Treatment at a Dose of 3 mg/kg in Paediatric Subjects with Chronic Hepatitis B (1 citation(s)) NUC30907 Phase 3 A randomized, double-blind, placebo-controlled study of the treatment of HBsAg positive patients after stable renal transplantation with lamivudine (1 citation(s)) NUC30910 Phase 2 Lamivudine for Prevention of HBV Reactivation in HBsAg Seropositive Patients undergoing Cytotoxic Chemotherapy (1 citation(s)) NUC30914 Phase 3 A multicentre, randomised, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of recombinant HBV vaccine and hepatitis B immunoglobulin (HBIg) plus lamivudine versus recombinant HBV vaccine and HBlg plus placebo for the prevention of mother-to-child transmission of HBV. (1 citation(s)) NUC30919 Phase 3 A double blind randomised multicentre study of lamivudine added to the current treatment in the therapy of chronic hepatitis B in HBV-DNA/anti-HBe positive Subjects. (0 citation(s)) NUC30925 Phase 4 An open-label, Phase-IV study to demonstrate the efficacy and safety of locally manufactured (Suzhou, China) Lamivudine tablets (100mg) in Chinese patients with chronic hepatitis B (CHB) (0 citation(s)) NUC30926 Phase 3 An Extended, Stratified Follow-on Study In Paediatric Subjects With Chronic Hepatitis B Who Have Completed Previous Lamivudine Studies (1 citation(s)) NUC30928 Phase 3 A multicentre, single-arm, non-randomised trial to evaluate the efficacy and safety of lamivudine 100mg once a day in patients with chronic hepatitis B virus infection. (1 citation(s)) NUC30931 Phase 4 Multicentre, open study to determine the effect of Lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection (3 citation(s)) NUC30933 Phase 3 A Study of the Safety and Efficacy of Lamivudine 100 mg OD in Egyptian Patients with Chronic Replicating Hepatitis B Virus (CHB). (0 citation(s)) NUC30935 Phase 3 A Randomised, Multicenter, Placebo-Controlled Study to Assess the Efficacy and Optimal Duration of Lamivudine Treatment in Patients with Pre-core Mutant HBV (0 citation(s)) NUC30937 Phase 4 An open label one year study of lamivudine in patients with chronic hepatitis. (0 citation(s)) NUC30938 Phase 3 A randomised trial of lamivudine plus interferon versus lamivudine for the treatment of HBeAg positive chronic hepatitis B virus (HBV) (1 citation(s)) NUC30944 Phase 4 A study of the safety and efficacy of Lamivudine 100 mg OD in patients with HBeAg negative (presumed pre-core mutant) chronic hepatitis B virus infection. (0 citation(s)) nuc30957 Phase 3 Phase III clinical study of GG714 (Lamivudine) Tablet - A double-blind, placebo-controlled study to investigate the efficacy and safety of Lamivudine 100 mg o.d. vs placebo in subjects with compensated cirrhosis B - (1 citation(s)) NUC30958 Phase 3 A Phase III Clinical Study of GG714 (Lamivudine) Tablet-A study of extended GG714 treatment for subjects with hepatitis B-related Cirrhosis (long-term study) (0 citation(s)) NUC40019 Phase 4 An open study to determine the safety and efficacy of lamivudine in subjects with chronic hepatitis B (0 citation(s)) NUC40021 Phase 4 A Stratified, Partially Randomised (Stratum B only), Double Blind, Multicentre Trial of Lamivudine and Adefovir Dipivoxil Treatment for Patients with Chronic Hepatitis B Who Have Shown Disease Progression by Reaching a Clinical Endpoint (2 citation(s)) NUC40031 Phase 4 Open study to determine the effect of Lamivudine on liver histology and DNA HBV suppression in patients after seroconversion in HBeAg and with HBsAg present (0 citation(s)) NUC40032 Phase 4 Pre-emptive Lamivudine and Chemotherapy-induced Hepatitis B Virus Reactivation in Patients with Hematologic Malignancies (0 citation(s)) NUC40036 Phase 4 An open-label, Phase IV study to examine whether the duration of lamivudine treatment following HBeAg seroconversion affects the durability of the HBeAg seroconversion response in Asian patients. (0 citation(s)) NUC40040 Phase 4 An Extended, Observational Study in Pediatric Patients with Chronic Hepatitis B Who Have Previously Received Long-Term Lamivudine Treatment (0 citation(s)) NUCA1004 Phase 1 A Single-Dose Study of GR109714X (3TCTM) in HIV-Infected Patients with Impaired Renal Function (1 citation(s)) NUCA1006 Phase 1 Bioequivalence of Lamivudine [GR109714X, 3TCTM] 75mg, 100mg, and 300mg Tablets in Asymptomatic HIV-Infected Male Patients (0 citation(s)) NUCA2002 Phase 2 A Phase I/II Study of 3TC (GR109714X) in Children With HIV Infection (6 citation(s)) NUCA2005 Phase 2 A phase I/II study to evaluate the safety, toxicity and preliminary efficacy of combinations of lamivudine (3TC), Zidovudine (ZDV) and Didanosine (ddI) in children with HIV infection. (0 citation(s)) NUCA2006 Phase 2 A Pilot Study to Assess the Safety and Efficacy of Lamivudine During the Course of Liver Transplantation for Patients with Chronic Hepatitis B Infection (0 citation(s)) NUCA2008 Phase 2 A Continuation Study of Lamivudine in Patients with Chronic Hepatitis B Infection (0 citation(s)) NUCA2010 Phase 3 Lamivudine Compassionate Use for Patients with Decompensated Liver Injury Secondary to Hepatitis B Infection (0 citation(s)) NUCA3001 Phase 3 A Randomized, Double-Blind, Multi-center Trial to Compare the Safety and Efficacy of 3TCTM Monotherapy Versus Zidovudine (ZDV) Monotherapy Versus 3TCTM Administered Concurrently with ZDV in the Treatment of HIV-1 Infected Patients who are ZDV-Naïve (?4 weeks) with CD4 Cell Counts of 200-500 cell ... (7 citation(s)) NUCA3002 Phase 3 A Randomized 3TCTM, ddC Double-Blind (ZDV Open-labeled) Multi-center Trial to Evaluate the Safety and Efficacy of 3TCTM (low dose) Administered Concurrently with Zidovudine (ZDV) versus 3TCTM (high dose) Administered Concurrently with ZDV Versus Dideoxycytidine (ddC) Administered… (1 citation(s)) NUCA3005 Phase 2 Lamivudine Open-label Protocol for Treatment of Patients with Hepatitis B Viral Infection After Liver Transplantation (0 citation(s)) NUCA3010 Phase 3 A Study of Lamiviudine or Placebo in Patients with Chronic Hepatitis B Infection Who are Treatment Naive (0 citation(s)) NUCA3016 Phase 3 A Five Year Final Study Report for NUCA/B3016 - A Long-Term Epidemiologic Study of Subjects Who Have Evidence of Possible Durable Response to Lamivudine in Phase II or Phase III Trials of Lamivudine (0 citation(s)) NUCA3021 Phase 3 Lamivudine Compassionate Use Treatment Program for Subjects with Three Life-Threatening Forms of Hepatitis B Infection (1 citation(s)) NUCAB3011 Phase 3 A Placebo Controlled Study of Lamivudine and Intron A in Patients with Chronic Hepatitis B Infection Who are Interferon a Non-Responders (0 citation(s)) NUCB1002 Phase 1 A Study to Investigate the Pharmacokinetics of Lamivudine (GR109714X) in Patients With Impaired Hepatic Function (Protocol No: C93-015) (0 citation(s)) NUCB1003 Phase 1 A Study to Investigate the Pharmacokinetics of Lamivudine (GR109714X) Following Oral Dosing in Subjects With Impaired Renal Function (0 citation(s)) NUCB1004 Phase 1 A study to investigate the comparative bioavailability of two oral formulations of GR109714X (Lamivudine). (0 citation(s)) NUCB1007 Phase 1 A Study to Investigate the Pharmacokinetic Interaction Between Lamivudine and Alpha-Interferon in Healthy Subjects (0 citation(s)) NUCB1009 Phase 1 A study to investigate the pharmacokinetics of lamivudine (GR109714X) in healthy male and female Chinese subjects. (0 citation(s)) NUCB2001 Phase 2 A phase I/II study of the safety, pharmacokinetics and preliminary activity of 3TC (GR109714X) in HIV-positive, asymptomatic and mild ARC patients. (0 citation(s)) NUCB2002 Phase 2 A Randomized, Multicentre, Single-blind (Patient), Placebo-controlled, Phase II, Dose-ranging Study to Determine the Pharmacokinetics, Safety and Preliminary Activity of Once Daily Lamivudine in Patients with Chronic Hepatitis B Infection (0 citation(s)) NUCB2003 Phase 2 A Randomized, Multicentre, Single Blind (Patient) Study to Compare the Efficacy and Safety of 25 mg, 100 mg, and 300 mg Lamivudine, Once daily in patients with Chronic Hepatitis B Infection (1 citation(s)) NUCB2004 Phase 2 A Randomized, Phase II, Single-blind (Patient), Placebo-controlled, Dose-ranging Study to Determine the Safety and Preliminary Activity of Lamivudine in Oriental Patients with Chronic Hepatitis B Infection (0 citation(s)) NUCB2005 Phase 2 A Randomised, Phase II, Single-blind (Patient) Placebo-controlled, Dose-ranging Study to Determine the Safety and Preliminary Activity of Lamivudine in Oriental Patients with Chronic Hepatitis B Infection (0 citation(s)) NUCB2007 Phase 2 A Double-blind, Placebo-controlled, Randomised, Parallel Group, Multicentre Study to Assess the Effect of Lamivudine on the Safety, Tolerability and Pharmacokinetics of Alpha-interferon in Patients Receiving Interferon for Chronic Hepatitis B Infection (0 citation(s)) NUCB2008 Phase 2 An Open, Multicentre Study to Determine the Safety, Pharmacokinetics and Preliminary Efficacy of Lamivudine in Chronic Hepatitis B Patients in End Stage Liver Failure Undergoing Liver Transplantation (1 citation(s)) NUCB2010 Phase 2 An Open Phase II Pilot Study to Determine the Safety and Activity of Lamivudine in Patients with Chronic Hepatitis C Infection (0 citation(s)) NUCB2013 Phase 2 An Open, Randomised, Multicentre Study to Compare the Safety and Efficacy of Lamivudine Versus Hepatitis B Immunoglobulin in the Prevention of Hepatitis B Reinfection After Liver Transplantation (1 citation(s)) NUCB2014 Phase 2 Multicentre, Open Label Compassionate Use Programme for Patients Treated with 100 mg Lamivudine Once Daily for up to 5 Years (0 citation(s)) NUCB2015 Phase 3 A Study of the Immunobiology of Patients with Chronic Hepatitis B Infection Treated with Lamivudine.Extensive searching has revealed that no clinical study report is available for this study. The Clinical trial results were reported via publication; see citation below. (1 citation(s)) NUCB2018 Phase 2 The Pharmacokinetics of Epivir (Lamivudine) When Co-Administered With Retrovir (Zidovudine) to HIV-1 Infected Pregnant Women and Their Offspring (1 citation(s)) NUCB2020 Phase 2 A Phase II, Dose Ranging Study of the Pharmacokinetics of Lamivudine in Children and Adolescents with Chronic Hepatitis B Virus Infection (3 citation(s)) NUCB2021 Phase 2 An Open, Single Centre Study to Determine the Safety, Pharmacokinetics and Preliminary Efficacy of Lamivudine in Chronic Hepatitis B Patients in End Stage Liver Failure (ESLF) Undergoing Liver Transplantation (1 citation(s)) NUCB3001 Phase 3 A Randomized, Controlled 3TCTM Double-Blinded Trial to Compare the Safety and Efficacy of 3TCTM in Combination with Zidovudine (ZDV) Versus Zidovudine Monotherapy in Treating HIV-1 Infected Patients Who Are Zidovudine Therapy-Naïve With a CD4 Cell Count Between 100 - 400 cells/mm3. (11 citation(s)) NUCB3002 Phase 3 A Randomized, Controlled, Lamivudine (3TCTM) Double-Blinded Trial to Compare the Safety and Efficacy of Zidovudine (ZDV) Monotherapy Versus Lamivudine Plus ZDV in Combination in Treating HIV-1 Infected Patients who are Zidovudine Therapy-Experienced With a CD4+ Cell Count Between 100cells/mm3 to ... (11 citation(s)) NUCB3007 Phase 3 A Randomized, Controlled, Double-Blinded, Clinical End-Point Trial to Compare the Efficacy and Safety of 3TC Versus 3TC + Loviride Versus Placebo in the Treatment of HIV-1 Infected Persons Taking Concurrent Zidovudine-Containing Treatment Regimens With CD4 Counts Between 25cells/mm3 to 250cells/mm3 (23 citation(s)) NUCB3009 Phase 3 A Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Two Dosage Regimens of Lamivudine in Patients with Chronic Hepatitis B Infection (1 citation(s)) NUCB3010 Phase 3 A Study of Lamivudine and Alpha-Interferon in Patients with Chronic Hepatitis B Infection Who are Interferon Treatment Naive (1 citation(s)) NUCB3014 Phase 3 A Study of Lamivudine in Patients With HBeAb Positive Chronic Hepatitis B Infection; Week 52 (End of Treatment) Analysis (1 citation(s)) NUCB3017 Phase 3 A Study of Extended Lamivudine Treatment for Hepatitis B Subjects Previously Enrolled in Phase II or Phase III Lamivudine Trials. (0 citation(s)) NUCB3018 Phase 3 A Follow-On Study to Determine the Safety and Efficacy of Long-Term Lamivudine Treatment in Patients with Chronic Hepatitis B Infection (5 Year Treatment Plus 6 Months Off-treatment Follow-Up) (4 citation(s)) NUCB3026 Phase 3 A Double-Blind, Placebo-Controlled Study Of Lamivudine In Subjects In China With Chronic Hepatitis B Infection Followed By Long-Term (5 Years) Lamivudine Treatment (0 citation(s)) NUCB4006 Phase 4 A Double-blind Placebo Controlled Clinical End-points Trial of Lamivudine in Patients with Hepatitis B Related Cirrhosis (1 citation(s)) ZEFT02 Phase 3 Open-label study of lamivudine in combination with interferon in treating chronic hepatitis B, anti HBe positive patients who are interferon-therapy naïve. (0 citation(s)) ZEFT03 Phase 3 Open label treatment with lamivudine in patients with chronic hepatitis B, Anti HBe (Hepatitis B envelope) Positive, who have not responded to previous treatment with interferon. Study of lamivudine added to the interferon treatment in comparison to the sequential treatment (0 citation(s))
